Singer Natalie Cole, who was diagnosed with chronic hepatitis C in 2008, will meet with leading patient advocates in Washington, D.C., and discuss the Tune In to Hep C national public health initiative, sponsored by Merck and the American Liver Foundation, at a National Press Club Speakers Luncheon, Wednesday, Oct. 19.
"There is a stigma around chronic hepatitis C because it's associated with IV drug use. But it doesn't matter how you got the virus, it matters what you do about it," Natalie Cole said in a statement. "That's why I've joined the Tune In to Hep C campaign to share my story and motivate people to take the next step by speaking to their doctor. Doing nothing is not an option."
HOUSTON - Houston Astros manager Brad Mills is more than pleased to prepare for the golden anniversary of the team in 2012 while helping some people with special medical needs before the season ends.
Mills is leading an initiative to help patients with Hepatitis-C, an infection of the liver that affects almost 3.2 million people in the U.S. He says anyone can be tested for the infection and the process can be rather quick.
MYFOXNY.COM - John Franco has more saves than any left-handed pitcher in history.
The former NY Mets pitcher who played 22 years in the major leagues, is now focused on raising awareness of Hepatitis C.
While Franco does not have the disease, he became concerned with possibly having contracted the disease while getting a tatoo decades ago.
Franco spoke with Good Day New York on Thursday about Hep C, a new campaign and what every New Yorker should do: get tested!
INCIVO® (Telaprevir) Approved In Europe Offering Higher Cure Rates For Genotype-1 Chronic Hepatitis C Compared To Standard TreatmentNew treatment options increase chance of a cure
Beerse, Belgium, (September 20, 2011) – Tibotec Virco-Virology BVBA, one of the Janssen Pharmaceutical Companies, announced today that the European Commission has approved INCIVO® (telaprevir), a direct acting antiviral (DAA) protease inhibitor, for the treatment of genotype-1 chronic hepatitis C virus (HCV), in combination with peginterferon alfa and ribavirin, in adults. With this new class of medicines, of which telaprevir is the latest addition, more genotype-1 chronic HCV patients than ever before will have the chance of a cure.
***DENISE GRADY Published: September 22, 2011
Improvements are needed in the screening of organ donors to protect transplant patients from hepatitis B and C, the Centers for Disease Control and Prevention said Wednesday. Transplant centers already test both living and dead donors for those diseases, but many centers use an older type of blood test that cannot detect an infection that was acquired very recently. A newer technique, nucleic acid testing, can find infections earlier. For hepatitis C, for instance, the older test cannot detect the disease during the first 70 days after infection. But nucleic acid testing can find it after seven days. The newer test is already used to detect H.I.V. Infections in organ recipients prompted the new recommendations. From 2007 to 2010, the C.D.C. confirmed dozens of cases of hepatitis B and C and H.I.V. caused by transplants; some patients died.
Bristol-Myers Squibb Co. (BMY)’s experimental hepatitis C drug worked in combination with two established medicines to cure as many as 83 percent of patients, a study found.
The trial tested three doses of the drug, called BMS-790052, with peginterferon and ribavirin, the standard treatment. Pills with the two highest doses cured 83 percent of patients 24 weeks after the treatment was completed, compared with 25 percent for those on the current therapies and a placebo, the New York-based company said in a statement today at ICAAC, the Interscience Conference on Antimicrobial Agents and Chemotherapy, in Chicago.
***Luke Timmerman 9/15/11
Cocrystal Discovery, the Bothell, WA-based drug discovery startup led by a couple of Icos veterans, has nailed down $7.5 million in new investment to develop a new kind of hepatitis C drug with Israel-based Teva Pharmaceutical.
Hepatitis C, a chronic liver-damaging virus that affects 170 million around the world, has clearly emerged as one of the hot areas in drug development as Cambridge, MA-based Vertex Pharmaceuticals (NASDAQ: VRTX) and Whitehouse Station, NJ-based Merck (NYSE: MRK) have each introduced new protease inhibitor drugs that have greatly increased the cure rate for this infection. Scientists are now working on a number of different antiviral combination therapies to see if they can continue to raise the cure rate, and get rid of standard medications that cause side effects.
BY THE PRESIDENT OF THE UNITED STATES OF AMERICA
Across our Nation, millions of Americans are living with viral hepatitis. As many as three-fourths of Americans living with the disease are unaware of their status and are not receiving care and treatment for their condition. Raising awareness about hepatitis is crucial to effectively fight stigmas, stem the tide of new infections, and ensure treatment reaches those who need it.
White House event in honor of the first official World Health Organization (WHO)-sponsored “World Hepatitis Day”(7/29/2011)
Judy Chu (CA-32), chairwoman of the Congressional Asian Pacific American Caucus (CAPAC): “While we make up 6 percent of the total U.S. population, we account for more than 50 percent of hepatitis B cases in this country.”
“The greatest tragedy was that their deaths were entirely preventable,” said Chu. “I want you to know you have allies in Congress. We will not give up until we eradicate this disease. It is time to put these silent killers to rest.”
HHS Combating the Silent Epidemic of Viral Hepatitis: Action Plan for the Prevention, Care and Treatment of Viral HepatitisThe Department of Health and Human Services is committed to ensuring that new cases of viral hepatitis are prevented and that persons who are already infected are tested; informed about their infection; and provided with counseling, care, and treatment. This plan provides concrete steps that individuals, stakeholders, providers, public health officials and policy-makers can take to improve the prevention and treatment of viral hepatitis.
Video of NVHR - sponsored rally at World Hepatitis Day in Washington DC - May 2010.
In order to reduce health disparities, the Office of Minority Health (OMH) and the Centers for Disease Control and Prevention (CDC) are facilitating the National Task Force on Hepatitis B to address the problem of this disease in the Asian and Pacific Islander (API) community.
Even though a vaccine to prevent Hepatitis B has been available since 1982, there are approximately 1.25 million people who live with chronic Hepatitis B virus (HBV) in the United States, according to the CDC. An estimated 45,000 of those infected are new immigrants, and approximately half of them are Asian and Pacific Islanders.
Key elements include increasing national awareness of the disproportionate impact, engaging stakeholders, and expanding the infrastructure needed to reduce the risk of chronic hepatitis B infection and its long-term complications.
Aymin Delgado-Borrego finds that only 1 percent of children estimated to have HCV in Florida are receiving potentially life-saving medical treatment.
Of the 12,155 children estimated to have HCV in Florida, only 1,755—or 14.4 percent—had been identified. What’s more, only 1.2 percent of the estimated number of infected children were actually receiving medical care.
“There is a frightening lack of awareness among both the public and clinicians about Hepatitis C virus infection in pediatric patients,” she says.
Tune In To Hep C Awareness Campaign - Stories from Rock stars.Tune In to Hep C is a national public health campaign created to educate people about chronic hepatitis C and the importance of taking action. The campaign was founded because – although chronic hepatitis C care is advancing – public understanding of the disease isn't moving at nearly the same pace.
In order to increase awareness of chronic hepatitis C, Gregg and Natalie have partnered with Merck and the American Liver Foundation on Tune In to Hep C to give the disease a stronger voice and encourage patients to take the next step by talking to their doctor or healthcare provider about their options.